Piper Sandler Maintains Overweight on Ocular Therapeutix, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on Ocular Therapeutix (NASDAQ:OCUL) and keeps the price target at $15.
June 14, 2024 | 4:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's analyst Joseph Catanzaro has reaffirmed an Overweight rating on Ocular Therapeutix, maintaining a price target of $15. This suggests continued confidence in the company's stock performance.
The reaffirmation of an Overweight rating and a $15 price target by a reputable analyst suggests positive sentiment and confidence in Ocular Therapeutix's stock performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100